GoldenGolden
DiscGenics

DiscGenics

DiscGenics is a biotechnology company developing stem cell therapies for the treatment of degenerative disc disease.

DiscGenics is a clinical-stage biopharmaceutical company that focuses on developing regenerative cell-based therapies that relief pain and restore function in patients who suffer from degenerative diseases of the spine.

The mission of DiscGenics is to improve the lives of those debilitated by degenerative diseases of the spine via the development of innovative regenerative therapies. The company is committed to achieving this mission by delivering quality products that meet up to or exceed the expectations and requirements of customers.

DiscGenics is led by a team of medical device and biologics industry executives, practicing clinicians and innovators in orthopedics, spinal and neurosurgical markets.

DiscGenics is harnessing the restorative potential of cells native to the intervertebral disc to develop what it believes will be a profound therapeutic option for millions of patients who suffer from the effects of low back pain.

Timeline

2007
DiscGenics was founded.

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

DiscGenics Announces that Cell Therapy IDCT has Passed the Initial Safety Review of its First-in-Human Clinical Trial for Degenerative Disc Disease

DiscGenics

Web

DiscGenics Announces that Cell Therapy IDCT has Passed the Initial Safety Review of its First-in-Human Clinical Trial for Degenerative Disc Disease

SPINEMarketGroup

Web

New Cell Therapy Could Help Millions Suffering from Back Pain

CCRM and GE Healthcare

Web

Documentaries, videos and podcasts

Title
Date
Link

DiscGenics' IDCT Cell Therapy for DDD

February 14, 2018

Companies

Company
CEO
Location
Products/Services
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.